Nguyen Phi-Yen, Sanderson Ben, Makama Maureen, Mills Kate, Ammerdorffer Anne, Gülmezoglu A Metin, Vogel Joshua P, McDougall Annie R A
Maternal, Child and Adolescent Health Program, Burnet Institute, Melbourne, Australia.
Concept Foundation, Geneva, Switzerland.
BJOG. 2025 Jun;132(7):867-879. doi: 10.1111/1471-0528.18106. Epub 2025 Mar 3.
To evaluate the effects of polyphenol-containing products during pregnancy on preeclampsia-related maternal and neonatal outcomes.
Systematic review and meta-analysis.
Nine databases and one trial registry, from inception to August 11th, 2023.
POPULATION/SAMPLE: Randomised controlled trials where women received polyphenolic-containing products (as standardised extracts or dietary supplements) compared to placebo or standard care.
All review stages were conducted by two independent reviewers. Random-effects meta-analysis with the Hartung-Knapp-Sidik-Jonkman method using a framework for studies with few events.
Clinical outcomes combining the core outcome set for preeclampsia and WHO's priority outcomes.
Fourteen trials investigating six candidates were included. In women with preeclampsia, the addition of epigallocatechin gallate (EGCG) to nifedipine may reduce the time needed to achieve blood pressure control (mean difference (MD) = -14.10 min, 95% CI -18.46 to -9.74) and increase the time to the next hypertensive crisis (MD = 3.10 h, 95% CI 2.35 to 3.85) compared to nifedipine alone (1 trial, 349 women; low certainty). Similarly, the addition of resveratrol to nifedipine may reduce the time needed to achieve blood pressure control (MD = -15.50 min, 95% CI -19.83 to -11.17) and increase the time to the next hypertensive crisis (MD = 2.50 h, 95% CI 2.09 to 2.91) (1 trial, 349 women; low certainty). No differences were observed for other outcomes or candidates (Salvia miltiorrhiza, Bryophyllum pinnatum , raspberry and cranberry extracts).
ECGC and resveratrol supplements have been investigated for potential effects in managing clinical signs and symptoms of preeclampsia; however, evidence on the clinical and adverse effects of polyphenols is limited and uncertain.
评估孕期含多酚产品对先兆子痫相关母婴结局的影响。
系统评价和荟萃分析。
九个数据库和一个试验注册库，检索时间从创建至2023年8月11日。
研究对象/样本：随机对照试验，其中女性接受含多酚产品（作为标准化提取物或膳食补充剂），并与安慰剂或标准护理进行比较。
所有综述阶段均由两名独立的评审员进行。采用Hartung-Knapp-Sidik-Jonkman方法进行随机效应荟萃分析，使用适用于事件较少研究的框架。
结合先兆子痫核心结局集和世界卫生组织优先结局的临床结局。
纳入了14项研究6种候选物的试验。对于先兆子痫女性，与单独使用硝苯地平相比，在硝苯地平中添加表没食子儿茶素没食子酸酯（EGCG）可能会减少实现血压控制所需的时间（平均差（MD）=-14.10分钟，95%置信区间-18.46至-9.74），并增加至下一次高血压危象的时间（MD = 3.10小时，95%置信区间2.35至3.85）（1项试验，349名女性；低确定性）。同样，在硝苯地平中添加白藜芦醇可能会减少实现血压控制所需的时间（MD = -15.50分钟，95%置信区间-19.83至-11.17），并增加至下一次高血压危象的时间（MD = 2.50小时，95%置信区间2.09至2.91）（1项试验，349名女性；低确定性）。对于其他结局或候选物（丹参、落地生根、树莓和蔓越莓提取物）未观察到差异。
已对EGCG和白藜芦醇补充剂在管理先兆子痫临床体征和症状方面的潜在作用进行了研究；然而，关于多酚临床和不良反应的证据有限且不确定。
